PLoS One by Arinaitwe, Emmanuel et al.
Intermittent Preventive Therapy with Sulfadoxine-
Pyrimethamine for Malaria in Pregnancy: A Cross-
Sectional Study from Tororo, Uganda
Emmanuel Arinaitwe1, Veronica Ades2, AndrewWalakira1, Boaz Ninsiima1, OliveMugagga1, Teja S. Patil3,
Alanna Schwartz3, Moses R. Kamya4, Sussann Nasr5, Michelle Chang5, Scott Filler6, Grant Dorsey3*
1 Infectious Disease Research Collaboration, Kampala, Uganda, 2Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco,
San Francisco, California, United States of America, 3Department of Medicine, University of California San Francisco, San Francisco, California, United States of America,
4Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda, 5Centers for Disease Control and Prevention, Atlanta, Georgia, United
States of America, 6 The Global Fund to Fight Acquired Immune Deficiency Syndrome, Tuberculosis, and Malaria, Geneva, Switzerland
Abstract
Background: Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is widely
recommended in sub-Saharan Africa to reduce the risk of malaria and improve birth outcomes. However, there are reports
that the efficacy of IPTp with SP is waning, especially in parts of Africa where antimalarial resistance to this drug has become
widespread.
Methodology/Principal Findings: We conducted a cross-sectional study of 565 HIV-uninfected women giving birth at
Tororo District Hospital in southeastern Uganda. The primary objective of the study was to measure associations between
use of SP during pregnancy from antenatal records and the risk of adverse outcomes including placental malaria, low birth
weight, maternal parasitemia and maternal anemia. The proportion of women who reported taking 0, 1, 2, and 3 doses of SP
during pregnancy was 5.7%, 35.8%, 56.6% and 2.0% respectively. Overall, the prevalence of placental malaria was 17.5%,
28.1%, and 66.2% by placental smear, PCR, and histopathology, respectively. In multivariate analyses controlling for
potential confounders, $2 doses of SP was associated with non-significant trends towards lower odds of placental malaria
by placental smear (OR= 0.75, p = 0.25), placental malaria by PCR (OR= 0.93, p = 0.71), placental malaria by histopathology
(OR= 0.75, p = 0.16), low birth weight (OR = 0.63, p = 0.11), maternal parasitemia (OR= 0.88, p = 0.60) and maternal anemia
(OR= 0.88, p = 0.48). Using a composite outcome, $2doses of SP was associated with a significantly lower odds of placental
malaria, low birth weight, maternal parasitemia, or maternal anemia (OR= 0.52, p = 0.01).
Conclusions/Significance: In this area of Uganda with intense malaria transmission, the prevalence of placental malaria by
histopathology was high even among women who reported taking at least 2 doses of SP during pregnancy. The reported
use of $2 doses of SP was not associated with protection against individual birth and maternal outcome measures but did
protect against a composite measure of any adverse outcome.
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Introduction
Malaria in pregnancy remains a widespread problem in sub-
Saharan Africa, where approximately one in four pregnant women
has evidence of infection with Plasmodium falciparum at the time of
delivery [1]. Placental malaria is associated with several adverse
outcomes including intrauterine growth restriction, preterm
delivery, low birth weight (LBW), stillbirth, early neonatal death,
and maternal anemia [1]. To reduce the burden of malaria and
improve birth outcomes, intermittent preventive treatment in
pregnancy (IPTp) with the drug sulfadoxine-pyrimethamine (SP) is
recommended by the World Health Organization and has been
widely adopted as a cornerstone of malaria control in most African
countries. A number of randomized controlled trials and
observational studies in the 1990s demonstrated the efficacy of
IPTp with SP in reducing the burden of malaria and improving
birth outcomes [2–5]. Older recommendations were that pregnant
women take at least 2 doses of SP during pregnancy, but recently
the WHO has updated their recommendations that SP be
provided at each scheduled focused antenatal-care visit in the
second and third trimesters [6].
Despite the widespread adoption of IPTp with SP as policy in
Africa, there is concern for the continued efficacy of this
intervention due to the spread of resistance, especially in East
Africa. Sulfadoxine-pyrimethamine belongs to the antifolate class
of antimalarial drugs and resistance is mediated by the ordered
accumulation of point mutations in the dihydrofolate reductase
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73073
(dhfr) and dihydropteroate synthase (dhps) genes. The dhfr/dhps
quintuple mutant has been strongly associated with SP treatment
failure and has recently reached levels .90% in parts of East
Africa [7,8]. Sulfadoxine-pyrimethamine is no longer recommend-
ed for treatment of malaria and recent studies have shown poor
efficacy when used for the prevention of malaria in pregnant
women and infants in Tanzania [9,10] and school aged children in
Uganda [11].
To assess the current effectiveness of IPTp with SP we
conducted a cross-sectional study among women giving birth in
an area of southeastern Uganda characterized by high malaria
transmission intensity and over 90% prevalence of the dhfr/dhps
quintuple mutant associated with resistance to SP [7]. SP use was
documented from antenatal cards and associated with various




The study protocol was approved by the Uganda National
Council of Science and Technology and the institutional review
boards of the University of California, San Francisco, Makerere
University, and the U.S. Centers for Disease Control and
Prevention. Written informed consent was sought from all
participants before being enrolled in the study.
Study Site, Participants and Design
This study was conducted in Tororo, an area of southeastern
Uganda with high malaria transmission intensity and an entomo-
logical inoculation rate recently estimated to be 125 infectious
bites per person per year in 2011–12 (Grant Dorsey, personal
communication). Study participants were women giving birth at
Tororo District Hospital (TDH), a government hospital that
provides antenatal services and free HIV testing to all pregnant
women. Using a cross-sectional study design, all pregnant women
with singleton births delivering at TDH who were known to be
HIV-uninfected were screened for enrollment if they delivered
between Monday 8:00 am through Friday 4:00 pm from February
28th through July 4th, 2011. Women were enrolled if they fulfilled
the following selection criteria: 1) SP use documented from
antenatal card if attended antenatal care, 2) HIV status known and
negative, 3) absence of reported antimalarial therapy other than
SP in the previous 1 month, and 4) provision of informed consent.
A standardized questionnaire was administered to all enrolled
women including review of their government issued antenatal
card. Information collected as part of the questionnaire included
demographics, previous pregnancies, bednet use, education level,
ownership of household items, and the number and timing of
doses of SP (for which administration is directly observed in the
antenatal clinic) and other medications. Delivery outcomes were
assessed and birth weight obtained using a digital scale (Seca,
Birmingham, U.K.). Data on gestational age was not collected
because information on last menstrual period was often missing
and if present thought to be inaccurate. Biological samples
collected included maternal finger prick for blood smear and
hemoglobin measurement and placental blood and tissue biopsy.
Laboratory Methods
Hemoglobin measurements from maternal blood were made
using a portable spectrophotometer (HemoCue, Ängelholm,
Sweden). Maternal and placental thick blood smears were stained
with 2% Giemsa for 30 minutes and examined for malaria
parasites by standard microscopy. Parasite density was estimated
by counting the number of asexual parasites per 200 white blood
cells and calculating parasites per mL, assuming a white blood cell
count of 8,000 cells per mL. A smear was judged to be negative if
no parasites were seen after review of 500 high-powered fields.
Final microscopy results were based on a rigorous quality control
system with re-reading all blood smears by a second microscopist
and resolution of any discrepancies by a third microscopist. PCR
for the detection of malaria parasites were performed on placental
blood stored on filter paper using nested PCR as previously
described [12].
Placental biopsies of approximately 1–2 cm61–2 cm from the
maternal side were collected using scissors and placed in 10%
neutral buffered formalin. After 24 hours, biopsies were trimmed
with a razor blade to 161 cm size and formalin replaced with
fresh neutral buffered formalin. Following 1–3 months of storage,
placental tissue was embedded in paraffin wax, microtome
sectioned and stained with 2% Giemsa, and hematoxylin and
eosin. Histopathological slides were examined using standard and
polarized light microscopy for hemozoin pigment in intervillous
fibrin, malaria parasites, and macrophages with hemozoin
pigment using standardized criteria as previously described [13].
Statistical Analysis
Data were double entered in Access (Microsoft Corporation,
Redmond, Washington, USA), and analyses performed using
STATA (Stata Corp., College Station, Texas, USA). The primary
exposure variable of interest was IPTp use with SP as indicated on
the participant’s antenatal card. Given the distribution of the
number of SP doses reported taken, SP usage was dichotomized
into ,2 doses vs. $2 doses of IPTp. Comparisons of character-
istics between the two SP usage groups were made using the chi-
squared or t-test. Three definitions of placenta malaria were used:
1) any parasitemia by placental blood smear, 2) detection of
parasites by PCR, and 3) any evidence of placental malaria by
histopathology. Maternal peripheral parasitemia was defined as a
positive blood smear and maternal anemia defined as a
hemoglobin level ,11 gm/dL. Low birth weight was defined as
,2500 gm. Univariate and multivariate analyses of associations
between SP usage and outcomes of interest were performed using
logistic regression. Covariates adjusted for in multivariate analyses
included maternal age, gravidity, bednet use, level of education,
transmission season, and a wealth index generated using principal
component analysis as previously described [14]. Characteristics
used to calculate the wealth index included number of people
sleeping in room with participant, and household ownership of
electricity, television, mobile phone, radio, bicycle, motorcycle,
refrigerator and toilet. A p-value of ,0.05 was considered
statistically significant.
Results
Study Profile and Participant Characteristics
A total of 581 women were screened and 565 enrolled (Figure 1).
Reasons for exclusion included reported antimalarial use in the
last month other than SP (n= 10), antenatal card unavailable if
attended antenatal clinic (n = 4), HIV status unknown (n= 1), and
refusal to provide informed consent (n = 1). Of the 565 women
enrolled, 32 (5.7%) women reported to have not taken any SP
doses during pregnancy, 202 (35.8%) reported taking 1 dose of SP,
320 (56.6%) reported taking 2 doses of SP, and 11 (2.0%) reported
taking 3 doses of SP (Figure 1). Characteristics of study
participants stratified by SP usage are presented in Table 1.
Maternal age, gravidity, bednet use the prior evening, and delivery
during a high transmission season were similar between those with
IPTp with SP and Placental Malaria
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,2 doses of SP and $2 doses of SP. Women who reported taking
$2 doses of SP were more likely to be in the higher wealth index
categories (p = 0.008) and had a trend towards a higher level of
education (p = 0.06).
Associations between SP Usage and Outcomes of
Interest
Overall the risk of placental malaria as defined by placental
blood smear, placental PCR, and histopathology were 17.5%,
28.1%, and 66.2%, respectively. Among 466 placental blood
samples that were negative by blood smear, 62 (13.3%) were
positive by PCR suggesting the presence of sub-patent parasitemia.
Histopathology was the most sensitive measure of placental
malaria with 235 of 404 (58.2%) of samples negative for both
placental blood smear and PCR having histopathological evidence
of placental malaria, the majority (76.2%) of which only had
evidence of malarial pigment indicative of past infection.
Associations between SP usage and various measures of placental
malaria are presented in Table 2. Compared to ,2 doses of SP,
$2 doses of SP was associated with modest trends towards a lower
Figure 1. Study profile. SP = sulfadoxine-pyrimethamine.
doi:10.1371/journal.pone.0073073.g001
Table 1. Characteristics of study participants stratified by number of SP doses reported taken.
Characteristic ,2 doses of SPa (n=234) $2 doses of SPb (n =331) P-value
Maternal age in years, mean (SD) 24.2 (6.1) 25.0 (6.1) 0.14
Previous pregnancies, n (%)
0 85 (36.3%) 98 (29.6%)
1 40 (17.1%) 75 (22.7%) 0.13
$2 109 (46.6%) 158 (47.7%)
Reported bednet use the prior evening, n (%)
None 67 (28.6%) 78 (23.6%)
Untreated net 16 (6.8%) 19 (5.7%) 0.30
ITN 151 (64.5%) 234 (70.7%)
Highest level of education completed, n (%)
None 18 (7.7%) 24 (7.3%)
Primary school 156 (66.7%) 191 (57.7%) 0.06
Secondary school or greater 60 (25.6%) 116 (51.1%)
Wealth index, n (%)
1st quartile 69 (29.5%) 73 (22.1%)
2nd quartile 69 (29.5%) 79 (23.9%) 0.008
3rd quartile 53 (22.7%) 81 (24.5%)
4th quartile 43 (18.4%) 98 (29.6%)
Delivery during high transmission seasonc, n (%) 111 (47.4%) 164 (49.6%) 0.62
aReported 0 (n = 32) or 1 (n = 202) doses of SP taken during pregnancy.
bReported 2 (n = 320) or 3 (n = 11) doses of SP taken during pregnancy.
cHigh transmission season May–June 2011.
doi:10.1371/journal.pone.0073073.t001
IPTp with SP and Placental Malaria
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odds of a positive placental blood smear (OR=0.75, p = 0.25),
positive placental PCR (OR=0.93, p = 0.71), and placental
malaria by histopathology (OR=0.75, p = 0.16), but none of
these associations reached statistical significance after controlling
for potential confounders. There was no significant interaction
between gravidity and associations between SP usage and various
measures of placental malaria. Considering only samples with a
positive placental blood smear, there was no difference in the
geometric mean parasite densities between those with $2 doses of
SP compared to those with ,2 doses of SP (1253 vs. 1267/mL,
p= 0.98).
Associations between the duration since the last reported dose of
SP taken and the risk of a positive placental blood smear and
placental malaria by histopathology are presented in Figure 2.
Women who reported taking SP 3–14 days prior to delivery had a
significantly lower risk of a positive placental blood smear
compared to those who reported taking their last dose of SP
more than 14 days prior to delivery (2.8% vs. 17.8%, p= 0.02).
Similar findings were seen when considering maternal peripheral
parasitemia (2.8% vs. 19.6%, p= 0.01). There was no association
between the timing of the last reported dose of SP taken and the
risk of active malaria defined as the presence of parasites using
histopathology (p= 0.48).
Considering birth outcomes, 545 infants survived, 13 were
stillborn, and 7 died shortly after birth prior to discharge. Overall
the risk of LBW was 9.9%. Compared to,2 doses of SP,$2 doses
of SP was associated with a modest trend towards a lower odds of
LBW (OR=0.63, p = 0.11), but this did not reach statistical
significance after controlling for potential confounders (Table 2).
When evaluating birth weight as a continuous outcome, there was
no significant difference between mean birth weight for women
who reported taking ,2 doses of SP vs. $2 doses of SP after
controlling for potential confounders (3066 vs. 3093 gm, p= 0.12).
Considering maternal outcomes, the overall risk of peripheral
parasitemia and anemia were 19.1% and 43.7%, respectively.
Compared to ,2 doses of SP, $2 doses of SP was not associated
with peripheral parasitemia (OR=0.88, p = 0.60) or maternal
anemia (OR=0.88, p= 0.48) after controlling for potential
confounders. When evaluating maternal hemoglobin as a contin-
uous outcome, there was no significant difference between mean
hemoglobin for women who reported taking ,2 doses of SP vs.
$2 doses of SP after controlling for potential confounders (11.1 vs.
11.2 gm/dL, p= 0.94). Based on a composite outcome, $2 doses
of SP was associated with a significantly lower odds (OR=0.52,
p = 0.01) of any of evidence of placental malaria, LBW, maternal
parasitemia, or maternal anemia (Table 2). There was no
significant interaction between gravidity and associations between
SP usage and various birth outcomes.
Discussion
In this cross-sectional study of HIV-uninfected women giving
birth at a district hospital in Uganda, 94.3% of women had
documentation of receiving at least one dose of SP during
pregnancy and 58.6% received at least 2 doses of SP. At the time
of this study, national recommendations were that women take at
least 2 doses of SP during pregnancy. Despite the high coverage of
IPTp with SP in this population, the risk of placental malaria was
17.5% by placental blood smear and 66.2% by histopathology.
Given the small numbers of women who did not report taking SP
or who reported taking .2 doses during pregnancy, comparisons
were only made between those with ,2 doses of SP versus those
with $2 doses of SP. Receiving $2 doses of SP was not
significantly associated with protection against placental malaria,
LBW, maternal parasitemia, or maternal anemia, however, there
was significant protection when using a composite including any of
these adverse outcomes.
IPTp with SP replaced weekly chloroquine prophylaxis for the
prevention of malaria in pregnancy in the mid 1990’s and is
currently recommended as policy for most countries in sub-
Saharan Africa. A systematic review published in 2007 of 4 trials
comparing IPTp with 2-dose SP to case management or placebo
reported that IPTp with SP was associated with a reduced risk of
placental malaria, LBW, and maternal anemia [15]. However,
these studies were conducted in areas of low-moderate SP
resistance defined as 14-day treatment failure rates of 19–26%.
More recent studies have suggested that IPTp with SP may no
longer be effective in some areas. In a cross-sectional study
conducted from 2002–05 in Tanzania, IPTp with any SP was not
associated with protection against placental malaria, LBW, or
maternal anemia compared to women who did report taking SP
[10]. Of note, this study was conducted in an area where 14-day
SP treatment failure rates in children increased from 41% to 68%
during the same period [16,17]. In a large cross-sectional study
conducted over a 9 year period in Malawi, IPTp with SP was
associated with a decreased risk of placental parasitemia, LBW,
and maternal anemia from 1997–2001, but not from 2002–2006
[18]. In two clinical trials from Uganda and Mozambique there
Table 2. Associations between use of IPTp-SP and outcomes at delivery.





,2 doses of SP
(n=234)
$2 doses of SP
(n =331)
Positive placental blood smear 49 (20.9%) 50 (15.1%) 0.67 (0.43–1.04) 0.07 0.75 (0.47–1.22) 0.25
Positive placental PCR 71 (30.3%) 88 (26.6%) 0.83 (0.57–1.20) 0.33 0.93 (0.63–1.37) 0.71
Placental malaria by histopathology 168 (71.8%) 206 (62.2%) 0.65 (0.45–0.93) 0.02 0.75 (0.50–1.12) 0.16
Low birth weight (,2500 gm) 30 (12.8%) 26 (7.9%) 0.58 (0.33–1.00) 0.05 0.63 (0.35–1.12) 0.11
Maternal peripheral parasitemia 50 (21.4%) 58 (17.5%) 0.78 (0.51–1.19) 0.25 0.88 (0.56–1.40) 0.60
Maternal anemia (Hb ,11 gm/dL) 107 (45.7%) 140 (42.3%) 0.87 (0.62–1.22) 0.42 0.88 (0.62–1.25) 0.48
Composite outcomeb 208 (88.9%) 263 (79.5%) 0.48 (0.28–0.80) 0.003 0.52 (0.31–0.87) 0.01
aAdjusted for maternal age, gravidity, bednet use, level of education, wealth index, and transmission season.
bAny of the following: placental malaria by any detection method, low birth weight, maternal peripheral parasitemia, or maternal anemia.
doi:10.1371/journal.pone.0073073.t002
IPTp with SP and Placental Malaria
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were no differences in maternal and fetal outcomes between
pregnant women randomized to IPTp with 2-dose SP plus
insecticide treated bednets (ITNs) versus ITNs alone [19,20].
Monitoring the efficacy of IPTp with SP is challenging as it is
generally not considered ethical to perform randomized clinical
trials with a placebo arm in high transmission areas. Surrogate
data from in vivo studies of SP for the treatment of symptomatic
malaria have been used in the past, however, SP monotherapy is
no longer recommended for the treatment of malaria in Africa.
The WHO now recommends evaluation of the in vivo efficacy of
SP in populations with asymptomatic parasitemia as a method of
monitoring the effectiveness of IPTp with SP [21]. In a recent
study of children with asymptomatic parasitemia from the same
area of Uganda where this study was conducted, SP was associated
with a decreased risk of parasitemia after 14 days compared to
placebo, however, the risk of treatment failure due to recrudes-
cence of resistance parasites was similar when follow-up was
extended to 42 days [11]. These results were similar to the findings
of this study, where SP appears to have a short-term but
temporary benefit in reducing the prevalence of parasitemia
detected by microscopy. An alternative method proposed for
monitoring the effectiveness of SP is the surveillance of molecular
markers of drug resistance. Single-point mutations accumulate in
an ordered fashion in the dhfr and dhps target genes and the
prevalence of the dhfr/dhps quintuple mutant has been correlated
with in vivo SP resistance [22]. In pregnant women from Kenya
the prevalence of the dhfr/dhps quintuple mutant increased from
7% in 1996–2000 to 88% in 2008–09 [23]. In studies from
Tanzania and our site in Uganda the prevalence of the dhfr/dhps
quintuple mutant has surpassed 90% [7,24]. In addition, a sixth
mutation at dhps codon 581 associated with high level SP resistance
has now been reported in areas of Tanzania and Kenya [23,24]
but has not been found at our study site in Uganda [7]. Indeed, SP
was classified as unsuitable for IPT in eight countries in East Africa
based on a geo-referenced database of SP resistance markers [25].
The results of this study and others suggest the efficacy of IPT with
SP may be diminishing in East Africa due to the spread of drug
resistance.
This study has several limitations. First, we used a cross-
sectional study design rather than a placebo-controlled random-
ized trial since SP for IPTp is the standard of care and withholding
it was not felt to be an option. Although we attempted to control
for potential confounding factors, the possibility of bias due to
unmeasured factors cannot be ruled out, limiting our ability to
make causal inferences. Second, SP use was based on documen-
tation from antenatal cards and not measured using a prospective
study design. However, reports from antenatal cards are likely
accurate given that SP administration is directly observed in the
antenatal clinic. Third, over 92% of women in this study reported
taking 1–2 doses of SP during pregnancy, therefore we lacked the
statistical power to compare outcomes between groups that
reported taking no SP or more than 2 doses of SP. Fourth, we
were unable to obtain accurate data on gestational age or
molecular markers of SP resistance markers, limiting the scope of
our analyses. Finally, we cannot rule out the possibility of a type II
error, i.e. the possibility that SP provided protection against
individual outcomes we were unable to detect due to a lack of
statistical power.
In summary, growing evidence from this study and others raise
questions about the continued efficacy of IPTp with 2-dose SP for
the prevention of placental malaria in areas of East Africa with a
high prevalence of SP resistance. Although these data do not
provide evidence that IPTp with SP should be abandoned, there is
certainly a need to evaluate strategies for chemoprevention in
Figure 2. Risk of a positive placental blood smear and active malaria defined as the presence of parasites using histopathology
stratified by number of days since last reported dose of SP taken.
doi:10.1371/journal.pone.0073073.g002
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pregnancy that will reduce this risk of placental malaria. Several
studies have investigated whether increasing the number of
recommended doses of SP would improve efficacy. In a
randomized controlled trial from an area with low SP resistance
in Mali, 3-dose SP was associated with a lower risk of placental
malaria, LBW and preterm birth compared with 2-dose SP [26].
Studies from Malawi in Zambia reported that among HIV-
infected and -uninfected women, IPTp with monthly SP was
superior to 2-dose SP [27–29]. In a recent systematic review and
meta-analysis among pregnant women in sub-Saharan Africa,
IPTp with 3 or more doses of SP was associated with a higher birth
weight and lower risk of LBW than the standard 2-dose regimens
[30]. Indeed, recent guidelines from the World Health Organi-
zation now recommends IPTp with SP for all pregnant women at
each scheduled antenatal visit given at least 1 month apart [6], a
policy that has now been adopted in Uganda. Future controlled
trials should also evaluate alternatives to SP including mefloquine,
artemisinin-based combination therapies, and azithromycin con-
taining combination therapies.
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